Results 91 to 100 of about 75,992 (272)
Nivolumab exposure in a hemodialysis patient with metastatic melanoma
, 2021 The effect of intermittent hemodialysis (IHD) on nivolumab serum concentrations in patients with severe renal impairment is largely unknown. Here, we present a 79-year-old patient with metastatic melanoma and end-stage renal disease on IHD three times a ...Gulikers, Judith L., Judith L. Gulikers, Robin M.J.M. van Geel, Aarts, Maureen J.B., Schreurs, Marco J.W., Litjens, Elisabeth J R, Litjens, Elisabeth J.R., van Geel, Robin M.J.M., Maureen J.B. Aarts, Elisabeth J.R. Litjens, Schreurs, Marco J W, Gulikers, Judith L, Sander Croes, Marco J.W. Schreurs, Croes, Sander, Aarts, Maureen J B, van Geel, Robin M J M +16 morecore +1 more sourceClinical utility of nivolumab in the treatment of advanced melanoma
, 2016 Ramsey Asmar,1 Jessica Yang,1 Richard D Carvajal1,2 1Department of Medicine, College of Physicians and Surgeons, 2Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA Abstract: Melanomas are highly immunogenic tumors that ...Yang J, Carvajal RD, Asmar Rcore Abstract CT083: Clinical activity, immune and molecular correlates of nivolumab vs. nivolumab plus bevacizumab vs nivolumab plus ipilimumab in metastatic renal cell carcinoma
, 2017 Background: Immune checkpoint blockade including anti-CTLA-4 (ipilimumab, BMS) and anti-PD1 (nivolumab, BMS) as monotherapies have been known to have clinical activity against metastatic renal cell carcinoma (MRCC), but with relatively low clinical ...Luis M. Vence, Jose A. Karam, Tenghui Chen, Chaan S. Ng, Rebecca S. Slack, Jorge M. Blando, Nizar Tannir, Christopher G. Wood, Hao Zhao, Jianjun Gao, Eric Jonasch, Sreyashi Basu, Matthew Campell, Kamran Ahrar, Priya Rao, Padmanee Sharma, Surena Matin, Hong Chen, James P. Allison +18 morecore +1 more sourceRandomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
Journal for ImmunoTherapy of CancerBackground Checkpoint inhibitor therapy has demonstrated overall survival benefit in multiple tumor types. Tumor mutational burden (TMB) is a predictive biomarker for response to immunotherapies.Alexandra Leary, Paolo A Ascierto, Michele Maio, Georgia Kollia, Jennifer Friedmann, Marina Tschaika, Patrick Schöffski, Jonathan Baden, Neeltje Steeghs, Parul Doshi, Massimo Di Nicola, Jean-Pierre Delord, Iwona Lugowska, Mauricio Burotto, David S P Tan, Anthony Gonçalves, Michael Schenker, Ning Huang, Tudor-Eliade Ciuleanu, Martin Richardet, Lorena Lupinacci, Julieta Grasselli, Jacqueline Vuky, Somasekhar Konduru, Sai Vikram Vemula, Ruta Slepetis, Misena Pacius, Quyen Duong +27 moredoaj +1 more sourceSpotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy
, 2017 Vyshak Alva Venur,1 Monika Joshi,2 Kenneth G Nepple,3 Yousef Zakharia1 1Division of Hematology Oncology and Bone Marrow Transplant, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, 2Division of Hematology ...Joshi M, Nepple KG, Zakharia Y, Venur VAcore Tumor Infiltrating Lymphocyte Therapy Combined With PD‐1/LAG‐3 Inhibition in Patients With Recurrent Platinum‐Resistant Ovarian Cancer
International Journal of Cancer, EarlyView.The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...Tine J. Monberg, Cathrine L. Lorentzen, Marie C. W. Westergaard, Trine Z. Iversen, Troels H. Borch, Marco Donia, Sigrid M. Mannering, Stine E. W. Banke, Özcan Met, Inge Marie Svane +9 morewiley +1 more sourceOverall survival with combined nivolumab and ipilimumab in advanced melanoma [PDF]
, 2017 BACKGROUND: Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma.Schadendorf D., Rutkowski, Piotr, Ivan Marquez-Rodas, Ascierto, P.A., Schadendorf D, Rutkowski P., Dummer R, Smylie, M., Wagstaff, J., Gonzalez R, Grob, J-J., Lao, C.D., Hogg, D., C. Lance Cowey, Haanen, J., Haanen, John, Marquez-Rodas I, Dummer R., McArthur G, Linda Rollin, Guidoboni M., Hill, Andrew, Ascierto PA, Sosman J., Dirk Schadendorf, Grob JJ, Larkin J, Jonathan Cebon, Carlino MS, Carlino, M.S., Celeste Lebbé, Grob, Jean-Jacques, Rollin L., Jedd D. Wolchok, Guidoboni M, Smylie M., Postow, M.A., Hill A., Hodi F. S., Maio M., Chiarion-Sileni, V., Margaret K. Callahan, Chiarion-Sileni V, Lebbe C, Jeffrey Sosman, Schadendorf, D., Piotr Rutkowski, Rollin L, Carlino M. S., Marquez-Rodas I., Bhore, R., Ferrucci, Pier F, Cowey CL, Gonzalez, Rene, Matteo S. Carlino, Callahan M. K., Vanna Chiarion-Sileni, Hogg, David, Ferrucci, P.F., Schadendorf, Dirk, Cebon J, Hodi FS, John Wagstaff, Bechter O., Pier F. Ferrucci, Dummer, R., Maio M, John Haanen, Callahan, M.K., Smylie M, Bhore R., Dana Walker, Hill, A., Smylie, Michael, Long G. V., Andrew Hill, Cebon, J., Walker D., Long, G.V., Wagstaff, John, Lebbe C., Lebbe, C., Hogg D, Gonzalez R., Bechter O, Cowey, C Lance, McArthur G., Larkin J., Massimo Guidoboni, Christopher D. Lao, Rutkowski, P., Michele Maio, Hill A, Maio, M., Ascierto P. A., Marquez-Rodas, I., David Hogg, Michael Smylie, Cowey, C.L., Wolchok, J.D., Wolchok J. D., Callahan MK, Cebon J., Wolchok JD, Sosman J, Dummer, Reinhard, Rene Gonzalez, Gonzalez, R., Jean-Jacques Grob, F. Stephen Hodi, Postow MA, Wagstaff J., Larkin, J., McArthur, G., Sosman, J., Bhore R, Grant McArthur, Haanen J, Bechter, Oliver, Wagstaff J, Paolo A. Ascierto, Carlino, Matteo S, Chiarion-Sileni V., Georgina V. Long, Postow M. A., Walker D, Cowey C. L., Chiarion-Sileni, Vanna, James Larkin, Reinhard Dummer, Oliver Bechter, Rutkowski P, Lao, Christopher D, Walker, D., Hogg D., Guidoboni, M., Ferrucci PF, Lao C. D., Grob J. -J., Ferrucci P. F., Haanen J., Hodi, F.S., Long GV, Rafia Bhore, Wolchok, Jedd D, et al, Rollin, L., Michael A. Postow, Lao CD +148 morecore +1 more sourceReal‐World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and Beyond
International Journal of Cancer, EarlyView.Progression after anti‐PD‐1‐based therapy is a predominant scenario in metastatic melanoma. However, real‐world data informing treatment of metastatic melanoma in later lines remains scarce. This retrospective nationwide, population‐based cohort study shows in a real‐world setting that nivolumab plus ipilimumab can induce durable responses beyond the ...Yago Garitaonaindia, Søren Kjær Petersen, Louise M. Guldbrandt, Troels H. Borch, Christina H. Ruhlmann, Rasmus Blechingberg Friis, Adam A. Luczak, Lars Bastholt, Henrik Schmidt, Inge Marie Svane, Eva Ellebaek, Marco Donia +11 morewiley +1 more sourcePartial response of pulmonary adenocarcinoma with symptomatic brain metastasis to nivolumab plus high-dose oral corticosteroid: a case report
Journal of Medical Case Reports, 2017 Background Nivolumab, a monoclonal antibody targeting the programmed death-1 receptor, is indicated in locally advanced or metastatic non-small cell lung cancer, with progression after platinum-based chemotherapy.Hélène Pluchart, Julian Pinsolle, Julien Cohen, Gilbert R. Ferretti, Pierrick Bedouch, Matteo Giaj Levra, Anne-Claire Toffart, Denis Moro-Sibilot +7 moredoaj +1 more source
